| Literature DB >> 28248222 |
Stuart Hesketh1, Kanchana Srisawat2, Hazel Sutherland3, Jonathan Jarvis4, Jatin Burniston5.
Abstract
The turnover of muscle protein is responsive to different (patho)-physiological conditions but little is known about the rate of synthesis at the level of individual proteins or whether this varies between different muscles. We investigated the synthesis rate of eight proteins (actin, albumin, ATP synthase alpha, beta enolase, creatine kinase, myosin essential light chain, myosin regulatory light chain and tropomyosin) in the extensor digitorum longus, diaphragm, heart and soleus of male Wistar rats (352 ± 30 g body weight). Animals were assigned to four groups (n = 3, in each), including a control and groups that received deuterium oxide (²H₂O) for 4 days, 7 days or 14 days. Deuterium labelling was initiated by an intraperitoneal injection of 10 μL/g body weight of 99.9% ²H₂O-saline, and was maintained by administration of 5% (v/v) ²H₂O in drinking water provided ad libitum. Homogenates of the isolated muscles were analysed by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionisation time of flight mass spectrometry. Proteins were identified against the SwissProt database using peptide mass fingerprinting. For each of the eight proteins investigated, the molar percent enrichment (MPE) of ²H and rate constant (k) of protein synthesis was calculated from the mass isotopomer distribution of peptides based on the amino acid sequence and predicted number of exchangeable C-H bonds. The average MPE (2.14% ± 0.2%) was as expected and was consistent across muscles harvested at different times (i.e., steady state enrichment was achieved). The synthesis rate of individual proteins differed markedly within each muscle and the rank-order of synthesis rates differed among the muscles studied. After 14 days the fraction of albumin synthesised (23% ± 5%) was significantly (p < 0.05) greater than for other muscle proteins. These data represent the first attempt to study the synthesis rates of individual proteins across a number of different striated muscles.Entities:
Keywords: 2D gel electrophoresis; cardiac muscle; deuterium oxide; mass isotopomer distribution analysis; matrix-assisted laser desorption ionisation mass spectrometry; protein synthesis; skeletal muscle; stable isotope labelling
Year: 2016 PMID: 28248222 PMCID: PMC5217367 DOI: 10.3390/proteomes4010012
Source DB: PubMed Journal: Proteomes ISSN: 2227-7382
Figure 1Separation of muscle proteins by 2-dimensional gel electrophoresis.
Protein identification by peptide mass fingerprinting.
| Protein | Score | Coverage | Peptide Sequence | CHNO | H–D | |
|---|---|---|---|---|---|---|
| ALBU | 170 | 27% | CPYEEHIK | 1075 | C45H67N11O14 | 17 |
| FKDLGEQHFK | 1248 | C58H85N15O16 | 13 | |||
| FPNAEFAEITK | 1266 | C59H87N13O18 | 21 | |||
| LGEYGFQNAVLVR | 1465 | C67H104N18O19 | 18 | |||
| DVFLGTFLYEYSR | 1609 | C77H108N16O22 | 17 | |||
| ACTS | 86 | 28% | AGFAGDDAPR | 976 | C41H61N13O15 | 25 |
| GYSFVTTAER | 1130 | C50H75N13O17 | 17 | |||
| AVFPSIVGRPR | 1198 | C55H91N17O13 | 23 | |||
| QEYDEAGPSIVHR | 1500 | C64H97N19O23 | 29 | |||
| SYELPDGQVITIGNER | 1791 | C77H123N21O28 | 26 | |||
| KCRM | 117 | 30% | FEEILTR | 907 | C42H66N10O13 | 14 |
| GYTLPPHCSR | 1187 | C49H75N15O14 | 19 | |||
| DLFDPIIQDR | 1231 | C55H86N14O18 | 15 | |||
| SFLVWVNEEDHLR | 1643 | C75H110N20O22 | 21 | |||
| GTGGVDTAAVGAVFDISNADR | 1992 | C83H113N25O32 | 39 | |||
| ENOB | 124 | 39% | IGAEVYHHLK | 1166 | C54H83N15O14 | 19 |
| VVIGMDVAASEFYR | 1556 | C70H109N17O21 | 26 | |||
| VVIGMDVAASEFYR | 1572 | C70H109N17O21 | 26 | |||
| AAVPSGASTGIYEALELR | 1804 | C79H129N21O27 | 42 | |||
| LAMQEFMILPVGASSFK | 1901 | C86H137N19O23 | 26 | |||
| ATPA | 137 | 34% | AVDSLVPIGR | 1026 | C45H79N13O14 | 19 |
| GIRPAINVGLSVSR | 1438 | C62H111N21O18 | 31 | |||
| TGAIVDVPVGDELLGR | 1611 | C70H119N19O24 | 28 | |||
| TPM1 | 163 | 38% | HIAEDADR | 926 | C37H59N13O15 | 23 |
| LDKENALDR | 1073 | C44H76N14O17 | 17 | |||
| LVIIESDLER | 1186 | C52H91N13O18 | 19 | |||
| KATDAEADVASLNR | 1460 | C59H101N19O24 | 31 | |||
| SIDDLEDELYAQK | 1538 | C59H101N19O24 | 23 | |||
| MYL3 | 91 | 44% | HVLATLGER | 995 | C43H74N14O13 | 18 |
| EAFLLFDR | 1010 | C48H71N11O13 | 15 | |||
| DQGGYEDFVEGLR | 1484 | C64H93N17O24 | 23 | |||
| DTGTYEDFVEGLR | 1501 | C65H96N16O25 | 21 | |||
| NKDTGTYEDFVEGLR | 1744 | C75H114N20O28 | 22 | |||
| MLRV | 119 | 63% | VFDPEGKGSLK | 1176 | C53H85N13O17 | 17 |
| DGFIDKNDKR | 1192 | C51H81N15O18 | 13 | |||
| EAFTIMDQNR | 1240 | C51H81N15O18 | 15 | |||
| NLVHIITHGEEKD | 1504 | C65H105N19O22 | 21 | |||
| LKGADPEETILNAFK | 1645 | C74H120N18O24 | 26 |
Albumin (ALBU), skeletal muscle alpha actin (ACTS), skeletal muscle creatine kinase (KCRM), beta-enolase (ENOB), ATP synthase alpha (ATPA), tropomyosin alpha-1 (TPM1), myosin essential light chain 3 (MYL3), myosin regulatory light chain slow/ventricular (MLRV). Score (MOWSE) and coverage (percent sequence coverage) reported from peptide mass fingerprinting and mascot searches against the Rattus Swiss-Prot database. Monoisotopic peak (m/z), elemental composition (CHNO) and number of exchangeable H–C bonds (H–D) are reported for each peptide.
Figure 2Mass spectrometry of deuterium-labelled peptides. Peptides were resolved as series of mass isotopomers (m0, m1, m2, ...) using matrix-assisted laser desorption ionisation mass spectrometry (MALDI-MS). Experimental mass spectra (red traces) from peptide DGFIDKNDLR (residues 41–50 of slow/ventricular myosin regulatory light chain; MLRV) are displayed from samples taken after 0, 4, 7 or 14 days of deuterium oxide (2H2O) administration in vivo. The blue trace represents the distribution of mass isotopomers predicted from the elemental composition of the peptide and the natural abundances of 12C, 1H, 14N and 16O (mMass software). The m0 (monoisotopic) peak is composed entirely of primary isotopes (i.e., 12C, 1H,14N and 16O), whereas m1, m2, m3 contain either 1, 2 or 3 “heavy“ isotopes (e.g., 13C, 2H, etc.).
Figure 3Time course of newly synthesised protein in vivo. The incorporation of deuterium in vivo was used to measure the synthesis of new protein using mass isotopomer distribution analysis. Data are presented as the average (Mean ± SEM) percentage of newly synthesised protein measured from 3–5 peptides for each protein, replicated in n = 3 biological samples. Data are fitted using a non-linear first-order equation. The range of the y-axis is consistent across muscles for each protein (i.e., by row) by differs between proteins (i.e., by column).
Half-time and rate constants (k) of protein synthesis in rat striated muscles calculated from 14 days 2H2O administration in vivo.
| Protein | Heart | Diaphragm | EDL | Soleus |
|---|---|---|---|---|
| Albumin (ALBU) | 11.0 ( | 11.0 ( | 14.4 ( | 13.3 ( |
| Actin (ACTS) | 20.2 ( | 28.7 ( | 87.8 ( | - |
| Creatine kinase (KCRM) | NA | 7.8 ( | 8.4 ( | NA |
| Beta enolase (ENOB) | NA | 21.1 ( | 24.2 ( | NA |
| ATP synthase α (ATPA) | NA | 25.2 ( | 28.9 ( | - |
| Tropomyosin (TPM1) | 28.5 ( | NA | 7.4 ( | - |
| Myosin essential light chain (MLY3) | 10.8 ( | 6.5 ( | 9.3 ( | - |
| Myosin regulatory light chain (MLRV) | 25.3 ( | NA | 47.8 ( | - |
Half-time in days and rate constant (k) of protein synthesis calculated from nonlinear regression of the change in newly synthesised protein measured at 4 days, 7 days and 14 days using mass isotopomer distribution analysis of deuterium-labelled muscles. NA = data not available due to inadequate data fitting.
Percentage of newly synthesised protein in rat striated muscles after 14 days 2H2O administration in vivo.
| Protein | Heart | Diaphragm | EDL | Soleus |
|---|---|---|---|---|
| Albumin (ALBU) | 17.2 ± 3.0 * | 29.2 ± 8.4 * | 25.1 ± 2.5 * | 20.6 ± 8.4 * |
| Actin (ACTS) | 2.0 ± 0.9 | 4.1 ± 1.3 | 1.5 ± 0.6 | - |
| Creatine kinase (KCRM) | 2.5 ± 1.2 | 8.4 ± 2.3 | 3.0 ± 1.5 | 9.5 ± 4.2 |
| Beta enolase (ENOB) | 5.5 ± 2.8 | 5.5 ± 1.4 | 6.9 ± 3.2 | 15.2 ± 5.1 |
| ATP synthase α (ATPA) | 0.5 ± 0.6 | 5.6 ± 2.3 | 13.2 ± 7.2 | - |
| Tropomyosin (TPM1) | 2.7 ± 1.2 | 3.0 ± 2.6 | 2.7 ± 2.1 | - |
| Myosin essential light chain (MLY3) | 5.8 ± 1.5 | 2.2 ± 3.0 | 11.4 ± 3.6 | - |
| Myosin regulatory light chain (MLRV) | 13.1 ± 5.3 | 12.2 ± 1.7 | 10.7 ± 2.3 | - |
Percentage of newly synthesised protein measured after 14 days deuterium oxide labelling in vivo. * p < 0.05, significantly different from other Proteins. All data are presented as Mean ± SEM of n = 3–5 peptides from each protein measured in n = 3 animals.
Figure 4Rank order of newly synthesised protein within each striated muscle. Data represent percentage (mean ± SD) of new protein synthesised after 14 days, presented in relative rank order within the heart, diaphragm, extensor digitorium longus and soleus.
Percentage of newly synthesised protein in rat striated muscles after seven days D2O administration in vivo.
| Protein | Heart | Diaphragm | EDL | Soleus | Triceps † |
|---|---|---|---|---|---|
| Albumin (ALBU) | 11.9 ± 2.4 | 20.2 ± 6.1 | 16.6 ± 2.7 | 13.6 ± 0.8 | - |
| Actin (ACTS) | 1.3 ± 0.6 | 2.6 ± 0.8 | 0.8 ± 0.5 | - | 7.0 ± 0.3 |
| Creatine kinase (KCRM) | 0.4 ± 0.3 | 5.9 ± 1.7 | 2.2 ± 1.0 | 1.0 ± 0.3 | 13.0 ± 0.4 |
| Beta enolase (ENOB) | 5.3 ± 0.3 | 4.0 ± 1.0 | 4.2 ± 1.2 | 7.5 ± 2.6 | 13.7 ± 0.3 |
| ATP synthase α (ATPA) | 0.3 ± 0.2 | 3.3 ± 1.0 | 8.1 ± 4.8 | - | 30.0 ± 1.2 |
| Tropomyosin (TPM1) | 1.6 ± 0.7 | 1.7 ± 1.6 | 2.0 ± 1.4 | - | 14.5 ± 0.4 |
| Myosin essential light chain (MLY3) | 1.2 ± 1.1 | 2.2 ± 2.1 | 7.2 ± 2.1 | - | 13.4 ± 1.6 |
| Myosin regulatory light chain (MLRV) | 7.9 ± 3.0 | 6.3 ± 1.3 | 5.6 ± 1.1 | - | 9.6 ± 0.3 |
† From Table 2 of Shankaran et al. 2015 [32].
(a)
| Synthesis (%) | m0 | m1 | m2 | m1/m0 | m2/m1 | em0 | em1 | em2 | em1/em0 | em2/em1 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0.5797 | 0.3288 | 0.0914 | 0.5672 | 0.2781 | -- | -- | -- | -- | -- |
| 25 | 0.5440 | 0.3450 | 0.1110 | 0.6341 | 0.3219 | −0.0357 | 0.0161 | 0.0196 | −0.4512 | 1.2162 |
| 50 | 0.5082 | 0.3611 | 0.1307 | 0.7105 | 0.3619 | −0.0715 | 0.0323 | 0.0392 | −0.4512 | 1.2162 |
| 75 | 0.4725 | 0.3772 | 0.1503 | 0.7983 | 0.3984 | −0.1072 | 0.0484 | 0.0588 | −0.4512 | 1.2162 |
| 100 | 0.4368 | 0.3933 | 0.1699 | 0.9006 | 0.4319 | −0.1430 | 0.0645 | 0.0784 | −0.4512 | 1.2162 |
(b)
| Precursor (%) | m0 | m1 | m2 | m1/m0 | m2/m1 | em0 | em1 | em2 | em1/em0 | em2/em1 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0.5797 | 0.3288 | 0.0914 | 0.5672 | 0.2781 | -- | -- | -- | -- | -- |
| 0.5 | 0.5472 | 0.3461 | 0.1067 | 0.6326 | 0.3082 | −0.0325 | 0.0173 | 0.0152 | −0.5315 | 0.8816 |
| 1.0 | 0.5168 | 0.3610 | 0.1223 | 0.6986 | 0.3387 | −0.0630 | 0.0321 | 0.0308 | −0.5105 | 0.9587 |
| 1.5 | 0.4883 | 0.3737 | 0.1380 | 0.7652 | 0.3694 | −0.0914 | 0.0448 | 0.0466 | −0.4902 | 1.0399 |
| 2.0 | 0.4617 | 0.3844 | 0.1539 | 0.8325 | 0.4005 | −0.1180 | 0.0555 | 0.0625 | −0.4705 | 1.1256 |
| 2.5 | 0.4368 | 0.3933 | 0.1699 | 0.9006 | 0.4319 | −0.1430 | 0.0645 | 0.0784 | −0.4512 | 1.2162 |
Predicted molar fraction of mass isotopomers (m0, m1, m2) at 0% synthesis (2a) or 0% precursor enrichment (2b) is subtracted from the molar fraction of mass isotopomers that include deuterium to give the enriched molar fraction of mass isotopomers (em0, em1, em2). In Table 2a, m1/m0 ratio is linearly associated with the fraction of newly synthesised protein. In Table 2b, the em2/em1 ratio is linearly associated with the level of precursor enrichment; the slope of these relationships is determined by the number of exchangeable C-H sites and the intercept is principally determined by the number of C atoms in the peptide. For example, the straight line equation of em2/em1 for peptide DGFIDKNDLR (C-H = 13, C = 51) is y = 0.1672x + 0.7936.